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SUMMARY
Introduction L-2-Hydroxyglutaric aciduria (L-2-HGA) is an autosomal recessive neurometabolic disease 
with a slowly progressive course and characterized by increased levels of hydroxyglutaric acid in urine, 
cerebrospinal fluid and plasma. In this condition clinical features mainly consist of mental deterioration, 
ataxia and motor deficits.
Case Outline The patient is a 16-year-old girl, the first and only child of healthy, non-consanguineous 
parents of Serbian origin. At the age of 4 years her walk became unsteady and ataxic. Other signs of 
cerebellar involvement were soon observed. Head circumference was above two standard deviations 
(55 cm). Mild mental retardation was revealed by formal intelligence testing (IQ 60). MR examination 
of the brain showed confluent subcortical white matter lesions spread centripetally, and atrophy of 
the cerebellar vermis with involvement of dentate nuclei, without deep white matter abnormalities. 
Laboratory investigation revealed increased amounts and a very large peak of HGA in urine and plasma. 
Enantiomeric analysis confirmed the L-configuration (>90%) establishing the diagnosis of L-2-HGA. The 
first epileptic seizure, partial with secondary generalization, occurred at age of 8 years. Favorable seizure 
control was achieved. A slow progression of neurological impairment was noted. Therapeutic trials with 
oral coenzyme Q10 and with oral riboflavin showed no biochemical and clinical effects. Recently, the 
diagnosis was proven by the presence of a mutation in the L-2-HGA gene.
Conclusion To our knowledge, this is the first report of L-2-HGA in Serbia. L-2-HGA must be considered 
in the differential diagnosis based on specific findings in cranial MRI.
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INTRODUCTION
L-2-Hydroxyglutaric aciduria (L-2-HGA) is an 
autosomal recessive neurometabolic disease, 
belonging to the group of organic acidurias with 
a slowly progressive course. It is characterized 
by increased levels of L-2-hydroxyglutaric acid 
in urine, cerebrospinal fluid and plasma [1]. 
L-2-hydroxyglutarate accumulates as a result 
of deficiency in flavin–adenine dinucleotide 
(FAD)-linked L-2-hydroxyglutarate dehydroge-
nase (L2HGDH), a mitochondrial enzyme con-
verting L-2-hydroxyglutarate to a-ketoglutarate. 
L-2-HGA is linked to the chromosome 14q22.1 
and its gene encodes a putative mitochondrial 
protein with homology to FAD-dependent ox-
idoreductases hydroxyglutaric aciduria [2, 3].   
So far, more than 30 mutations have been re-
ported in the L2HGDH gene [4].
L-2-HGA was first described in 1980 and 
since then more than 200 cases have been re-
ported worldwide. The clinical diagnosis is 
often delayed because of the insidious onset of 
symptoms [5]. Although the disease is usually 
of early infantile onset, it may be diagnosed in 
adults with a somewhat milder phenotype [4, 
6]. A solitary large and persistent increase of 
L-2-hydroxyglutaric acid in urine was reported 
for the first time in 1980 in a 5-year-old boy 
from Morocco (Berber), who was investigated 
for nonspecific mental and motor delay and 
growth deficiency [7]. Nevertheless, a distinct 
clinical and neuroradiological picture has 
emerged, as the disease has a relatively con-
sistent pattern of presentation.
Patients usually display a delayed mental 
and motor development in the first years of 
life. About two-third of them have epilepsy and 
cerebellar dysfunction with progressive ataxia, 
dysarthria and moderate to severe mental de-
terioration. Macrocephaly, pyramidal and ex-
trapyramidal signs and dystonia are present in 
the majority of patients [8, 9].
Briefly, magnetic resonance imaging (MRI) 
findings, which seem to be consistently unique 
of L-2-HGA, are very specific and affect the 
central white matter, basal ganglia, and cerebel-
lum [10]. Neuroimaging findings include sub-
cortical white matter loss and abnormalities of 
the dentate nucleus, globus pallidus, putamen, 
and caudate nucleus [9].
It has been suggested that the deficiency of 
L2HGDH induces a neoplastic state [11] and 
that patients with L-2-HGA have a predispo-
sition to cerebral neoplasms of various types, 
including medulloblastoma and glioblastoma 
[11, 12, 13]. There is no effective therapy. Iso-
lated cases are reported of successful treatment 
with riboflavin and FAD sodium and levocar-
nitine chloride supplements [11, 14].
CASE REPORT
The patient was a 16-year-old girl, the first 
and only child of healthy, non-consanguineous   
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parents of Caucasian, Serbian origin. Family history was 
uninformative. Pregnancy was uneventful. Caesarean sec-
tion was performed, as an elective procedure, because of 
the fetal malpresentation. Birth weight was 2800 g, birth 
length 50 cm and head circumference 36 cm. The neonatal 
period was normal. A psychomotor delay was evident in 
the second year of life. She was able to stand up and walk 
without support at about 26th months of life. Development 
of her speech was delayed.
At the age of 4 years her gait became worse, she was 
unsteady, with ataxic walk and other signs of cerebellar 
involvement as dysmetria, truncal ataxia, intention tremor 
and dysarthria. Her head circumference was above two 
standard deviations (55 cm). Psychomotor development, 
measured with the Brunet-Lezine scale, showed the de-
velopment quotient of 60. Ocular fundus examination 
was normal, but high degree myopia had been diagnosed. 
Electroencephalogram (EEG) showed diffuse non-specif-
ic abnormalities. Molecular genetic tests for Friedreich’s 
ataxia were negative. Electroneurographic examination 
was normal.
Magnetic resonance imaging of the brain performed 
at age of 4 years, showed diffuse, bilaterally symmetric 
T2 white matter hyperintensity, with atrophy of the cer-
ebellum suspected to be one of leukoencephalopathies ac-
companied by macrocephaly as Canavan leukodystrophy 
(Figure 1). Follow-up MR imaging and MR spectroscopy 
(done at age 8 years) showed confluent subcortical white 
matter lesions predominantly of the frontal-parietal lobes, 
atrophy of the cerebellar vermis with involvement of the 
dentate nuclei, without deep white matter abnormalities 
(normal appearance of corpus callosum, internal capsule, 
periventricular white matter) and the diagnosis of L-2-
HGA was suggested (Figures 2 and 3). Arcuate U fibers 
affection and centripetal involvement were seen. The 
subsequent screening for inborn errors of metabolism in-
cluded the analysis of amino acids, organic acids, oligosac-
charides, mucopolysaccharides, very long-chain fatty acids 
and lysosomal enzymes. Urine and blood samples were 
analyzed at the Erasmus University Metabolic Center in 
Rotterdam. Repeated urinary organic acid analyses per-
formed by gas chromatography and mass spectrometry 
(GC-MS) revealed highly increased amounts and a very 
large peak of 2-hydroxyglutaric acid. L-2-HGA in urine 
was 1740 mmol/mol of creatinine (controls <18.6) while 
in plasma it was 32 μmol/L (controls 0.3-1). Further enan-
tiomeric analysis confirmed the L-configuration (>90% 
L-2-HG) establishing the diagnosis of L-2-HGA.
The first epileptic seizure, partial with secondary gener-
alization, occurred at age of 8 years. After repeated unpro-
voked seizures and EEG examination (bilateral paroxysmal 
activity with focal discharges over the left parietal-tempo-
ral region) antiepileptic therapy with valproate (VPA) was 
started. With VPA 1g/daily (92 μg/ml) a partial control 
of seizure was achieved. Comedication with lamotrigine 
was introduced, resulting in improved seizure control (1 
complex partial seizure monthly). EEG records improved 
in time with nonspecific right-sided abnormalities. Since 
April 2010 levetiracetame (2 g/daily) was added to lamo-
trigine (300 mg/daily), while VPA was withdrawn. Favo-
rable seizure control was achieved.
Additional neurological signs and symptoms occurred 
over time, such as increased tremor, distal dystonia, oro-
facial dyskinesia and pyramidal signs (bilateral clonus, hy-
perreflexia and spastic hypertonia). At the age of 6 years, 
a mild mental retardation was revealed by formal intelli-
Figure 3. MRI – axial T2 weighted image: hyperintensity involving 
brain stem and cerebellum. Atrophy of the cerebellar vermis (black 
arrow) and of the dentate nuclei (white arrow).
Figure 1. Cerebral MRI of the patient. Axial T2 weighted image. Multi-
ple white matter hyperintensities with a frontal predomination (a) and 
without major deep and periventricular abnormalities (b). Affection 
of arcuate U fibers and centripetal involvement are shown (a and b).
Figure 2. MRI – coronal T2 weighted image: confluent subcortical 
white matter lesions predominantly of frontal-parietal lobes and at-
rophy of the cerebellar vermis (black arrow)     
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gence testing (IQ 60) without later deterioration. Her head 
circumference stopped increasing, but remained signifi-
cantly above the 97th percentile (60 cm).
Because of spastic pes equinovarus, her walk was pos-
sible with assistance only. She developed lumbosacral 
scoliosis. A retention orthosis was recommended at age 
of 12. Last year applied therapy with botulinus toxin was 
beneficial and resulted in decreased spasticity. In 2011 the 
diagnosis was proven by the presence of a mutation in the 
L-2-HGA gene (missense mutation c.185C>A located in 
the exon 2). Therapeutic trials with oral coenzyme Q10 
(400 mg/day) during 6 months and with oral riboflavin 
(200 mg/day) during 4 months showed neither biochemi-
cal nor clinical effects.
DISCUSSION
The progression of L-2-HGA and the consequent disabil-
ity are different among patients. Topçu et al. [15] report 
the clinical features of 29 patients from 22 families. The 
mean age at the time of diagnosis was 13.4 years (2.5-32 
years). The main clinical findings were mental retardation 
and cerebellar involvement with ataxic gait and intention 
tremor. Additional findings were mental retardation, mac-
rocephaly and seizures. During the follow-up period (1.5-
16 years), all patients had a static encephalopathy course.
In a group of 7 Italian patients, three patients developed 
severe motor and mental impairment with epilepsy, and 
worsened rapidly. One patient was severely demented, with 
spastic tetraparesis, ataxia and frequent seizures and died 
at 21 years of age. Other patients had milder cerebellar 
symptoms and mental retardation. Their clinical follow-up 
showed a slow progression of the disease [12]. Our patient 
presented with symptoms of cerebellar involvement at age 
of 4 years, additionally to the developmental delay, psycho-
motor regression and macrocephaly, as usually reported.
Macrocephaly is present in almost 50% of patients 
with L-2-HGA and it can be the first manifestation of the 
disease [16]. Therefore, it could be seen in other organic 
acidurias, such as glutaric aciduria type I, HMG-CoA 
lyase deficiency and 3-methylglutaconyl-CoA-hydratase 
deficiency [17]. Initial manifestation of severe autism and 
pervasive developmental disorders has been very rarely 
described in patients with L-2-HGA [16].
Seizures occur in more than 50% of patients with L-2-
HGA, usually late in the course of the disease [8]. Epileptic 
seizures or even status epilepticus can be found among 
the presenting symptoms in organic acidurias with a slow 
course, such as L-2-HGA [17]. A patient with neonatal 
onset of L-2-HGA showed a burst suppression pattern on 
EEG, making this disorder another entity, which should 
be considered in the differential diagnosis of neonatal sei-
zures [18]. The patient, a 9-month-old female infant, ho-
mozygous for the p.Lys81Glu (c.241A>G) missense muta-
tion in the L-2-HGA gene, was reported with acute hemi-
convulsion-hemiplegia-epilepsy syndrome as a presenting 
feature [19]. A 5-year-old boy with eyelid myoclonia with 
absences, bilaterally synchronous EEG polyspike/spike and 
wave discharges and L-2-OHG was described. The patient 
became seizure-free with a combination therapy of clon-
azepam, levetiracetam, and lamotrigine [20]. Our patient 
presented with complex partial seizures with secondary 
generalization. Favorable seizure control was achieved 
with valproate, lamotrigine and levetiracetam in combi-
nations.
Marked intra- and inter-familial variability in clinical 
phenotype has been reported [16, 21]. In the majority of 
cases, as in our patient, the severity of associated neurolog-
ic and cognitive impairments appears to progress slowly, 
with many of them surviving adulthood. However, a sud-
den deterioration may occur in occasional cases and some 
patients have a downhill neurologic course at a later age, 
sometimes as late as at 6-17 years of age [8]. There is one 
report of a neonate with L-2-HGA and a rapidly fatal out-
come [18]. An 11-month-old girl, born to consanguineous 
parents of Tamil origin suddenly died at 11 months of age, 
during an intercurrent illness [22]. There was no correla-
tion between the severity of clinical symptoms and the 
amount of L-2-OHG acid in urine or CSF [12]. Delay of 
L-2-HGA diagnosis until adulthood has been described [5, 
14], because of mild clinical symptoms and lack of typical 
MRI abnormalities [4].
Neuroimaging findings of L-2-HGA are very specific. 
Cranial MRI reveals characteristic scattered or diffuse sub-
cortical white-matter abnormalities fading centripetally 
[14]. A retrospective review of MR images in patients with 
L-2-HGA disclosed that initially, abnormalities of subcor-
tical white matter were at least partially multifocal, later 
became more confluent and spread centripetally, but the 
periventricular rim remained relatively spared. Bilateral in-
volvement of the globus pallidus, caudate nucleus, putamen 
and dentate nucleus was seen at all stages. The cerebellar 
white matter was never affected [9]. Confluent subcorti-
cal white matter lesions, atrophy of the cerebellar vermis 
with involvement of the dentate nuclei, without deep white 
matter abnormalities, were shown on MRI scans in our 
patients, supporting the diagnosis of L-2-HGA.
In all Turkish patients MRI showed subcortical leu-
koencephalopathy with bilateral high signal intensity in 
the dentate nuclei and putamens [15]. Atypical imaging 
anomalies, such as basal ganglia atrophy were described 
in an adult patient with L-2-OHG [5]. Moroni et al. [12] 
observed a good correlation between the severity of the 
disease and the extent of lesions on MRI. As cranial MRI 
findings raise suspicion of L-2-HGA, one must consider 
other diseases that have similar MRI findings for a dif-
ferential diagnosis. These diseases include Van der Knaap 
disease, Canavan disease and Alexander disease. We en-
countered the same initial diagnostic difficulties.
Increased incidence of brain tumors has been noted 
among patients with L-2-HGA [12]. Meta-analysis of pub-
lished data identified 14 patients with L-2-HGA associated 
with cerebral neoplasms, suggesting an approximately 5% 
prevalence rate of CNS neoplasms in these patients [13]. A 
male infant with L-2-HGA and Wilms tumor, the most com-
mon renal malignancy of childhood, was reported as exam-
ple of an extracranial tumor associated with L-2-HGA [11].     
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Neither cerebral nor extracranial neoplasm was found in 
our patient.
A possible therapeutic role of FAD, cofactor of the 
enzyme, and of its precursor riboflavin was investigated. 
Nevertheless, it appears that this approach is only effective 
in “mild” missense mutations of L2HGDH (supplementa-
tion with FAD 30 mg/day) and levocarnitine chloride (900 
mg/day)), whereas truncated enzymes (presumed null mu-
tations) are not responsive [1]. Therapeutic trials with oral 
coenzyme Q10 (400 mg/day) during 6 months and with 
oral riboflavin (200 mg/day) during 2 months showed no 
biochemical and clinical effects [22]. We could confirm 
this observation in our patient. No significant clinical ben-
efit of oral coenzyme Q10 (400 mg/day) during 6 months 
and with oral riboflavin (200 mg/day) during 4 months 
was noted.
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КРАТАК САДРЖАЈ
Увод L-2-хи  дрок  си  глу  та  рич  ка аци  ду  ри  ја (L-2-ХГА) је ауто-
зом  но ре  це  сив  на ме  та  бо  лич  ка бо  лест са спо  ро про  гре  сив-
ним то  ком, ко  ја се од  ли  ку  је по  ви  ше  ним ни  во  и  ма хи  дрок  си-
глу  та  рич  ке ки  се  ли  не (L-2-ХГ) у мо  кра  ћи, це  ре  бро  спи  нал  ној 
теч  но  сти и пла  зми. Кли  нич  ка сли  ка нај  че  шће укљу  чу  је мен-
тал  ну на  ру  ше  ност, атак  си  ју и мо  тор  не ис  па  де.
При  каз бо  ле  сни  ка Ше  сна  е  сто  го  ди  шња бо  ле  сни  ца ро  ђе  на 
је као пр  во и је  ди  но де  те здра  вих ро  ди  те  ља срп  ског по  ре-
кла и без крв  ног срод  ства. У уз  ра  сту од че  ти  ри го  ди  не ње  но 
хо  да  ње је по  стало не  ста  бил  но и атак  сич  но. Дру  ги зна  ци за-
хва  ће  но  сти ма  лог мо  зга, ди  сме  три  ја, атак  си  ја тру  па, ин  тен-
ци  о  ни тре  мор и ди  зар  три  ја, за  па  же  ни су вр  ло бр  зо. Обим 
гла  ве је био из  над две стан  дард  не де  ви  ја  ци  је (55 cm). Бла  га 
ум  на за  о  ста  лост по  ка  за  на је фор  мал  ном про  це  ном ин  те  ли-
ген  ци  је (IQ је био 60). Маг  нет  на ре  зо  нан  ци  ја мо  зга по  ка  за  ла 
је кон  флу  ент  на, суп  кор  ти  кал  на оште  ће  ња бе  ле ма  се са цен-
три  пе  тал  ним ши  ре  њем и атро  фи  ју ма  ло  мо  жда  ног вер  ми  са 
уз за  хва  ће  ност ден  тат  них је  да  ра, без оште  ће  ња ду  бо  ке бе  ле 
ма  се. Ла  бо  ра  то  риј  ска ис  пи  ти  ва  ња по  ка  за  ла су ве  о  ма ви  со  ке 
вред  но  сти L-2-ХГ у мо  кра  ћи и пла  зми. Енан  то  ме  рич  ка ана-
ли  за по  твр  ди  ла је Л-кон  фи  гу  ра  ци  ју (>90% L-2-ХГ), чи  ме је 
по  ста  вље  на ди  јаг  но  за L-2-ХГА. Пр  ви епи  леп  тич  ки на  пад, жа-
ри  шни са се  кун  дар  ном ге  не  ра  ли  за  ци  јом, ја  вио се у осмој го-
ди  ни. По  стиг  ну  та је по  вољ  на кон  тро  ла на  па  да. За  па  же  но је 
спо  ро на  пре  до  ва  ње не  у  ро  ло  шке на  ру  ше  но  сти. Те  ра  пиј  ска 
орал  на при  ме  на ко  ен  зи  ма Q10 и ри  бо  фла  ви  на ни  је до  ве  ла 
до би  о  хе  миј  ских и кли  нич  ких ефе  ка  та. Уско  ро је ди  јаг  но  за 
по  твр  ђе  на на  ла  зом му  та  ци  је L-2-ХГА ге  на.
За  кљу  чак Ко  ли  ко нам је по  зна  то, ово је пр  ви при  каз бо  ле-
сни  ка са L-2-ХГА у Ср  би  ји. У скла  ду с кли  нич  ком сли  ком и 
маг  нет  но  ре  зо  нант  ним сним  ком мо  зга, L-2-ХГА тре  ба да се 
увр  сти у ди  фе  рен  ци  јал  ну ди  јаг  но  сти  ку не  у  ро  ме  та  бо  лич  ких 
бо  ле  сти.
Кључ  не ре  чи: хи  дрок  си  глу  та  рич  ка аци  ду  ри  ја; епи  леп  си  ја; 
оште  ће  ња бе  ле ма  се; атак  си  ја
L-2-хидроксиглутаричка ацидурија: приказ болесника
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